Exelixis, Inc. (EXEL)
59.01
-0.12
(-0.20%)
USD |
NASDAQ |
Sep 04, 16:00
58.99
-0.02
(-0.03%)
After-Hours: 20:00
Exelixis Research and Development Expense (Quarterly) : 211.99M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 211.99M |
| March 31, 2026 | 199.92M |
| December 31, 2025 | 213.25M |
| September 30, 2025 | 199.16M |
| June 30, 2025 | 200.36M |
| March 31, 2025 | 212.23M |
| December 31, 2024 | 249.00M |
| September 30, 2024 | 222.57M |
| June 30, 2024 | 211.15M |
| March 31, 2024 | 227.69M |
| December 31, 2023 | 244.67M |
| September 30, 2023 | 332.58M |
| June 30, 2023 | 232.57M |
| March 31, 2023 | 234.25M |
| December 31, 2022 | 336.82M |
| September 30, 2022 | 198.84M |
| June 30, 2022 | 199.48M |
| March 31, 2022 | 156.67M |
| December 31, 2021 | 222.27M |
| September 30, 2021 | 163.37M |
| June 30, 2021 | 148.79M |
| March 31, 2021 | 159.29M |
| December 31, 2020 | 154.28M |
| September 30, 2020 | 176.76M |
| June 30, 2020 | 114.93M |
| Date | Value |
|---|---|
| March 31, 2020 | 101.88M |
| December 31, 2019 | 94.45M |
| September 30, 2019 | 97.30M |
| June 30, 2019 | 81.93M |
| March 31, 2019 | 63.29M |
| December 31, 2018 | 57.27M |
| September 30, 2018 | 44.74M |
| June 30, 2018 | 42.49M |
| March 31, 2018 | 37.76M |
| December 31, 2017 | 32.20M |
| September 30, 2017 | 28.54M |
| June 30, 2017 | 28.21M |
| March 31, 2017 | 23.21M |
| December 31, 2016 | 23.80M |
| September 30, 2016 | 20.26M |
| June 30, 2016 | 22.98M |
| March 31, 2016 | 28.93M |
| December 31, 2015 | 23.47M |
| September 30, 2015 | 26.09M |
| June 30, 2015 | 24.51M |
| March 31, 2015 | 22.28M |
| December 31, 2014 | 39.65M |
| September 30, 2014 | 43.63M |
| June 30, 2014 | 50.98M |
| March 31, 2014 | 54.85M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| BioMarin Pharmaceutical, Inc. | 206.95M |
| Cytokinetics, Inc. | 94.18M |
| Emergent BioSolutions, Inc. | 9.20M |
| Gilead Sciences, Inc. | 1.69B |